HIV/AIDS

New information on TRIZIVIR presented at conference

Published in AIDS Weekly, November 29th, 2004

GlaxoSmithKline (GSK) announced that new information from ongoing clinical trials investigating varied clinical applications for TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine) were presented at the 44th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

TRIZIVIR, the first tablet to combine three medications for HIV, is a fixed-dose-combination tablet containing three nucleoside reverse transcriptase inhibitors (NRTIs).

"These data help demonstrate the versatility of TRIZIVIR as a treatment for HIV in different clinical situations, and illustrate GSK's ongoing commitment to simplify HIV treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry